BIOGNOSYS
21.10.2021 16:02:05 CEST | Business Wire | Press release
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).
Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars . In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys:
“Our major contribution to the ASMS scientific program is a testimony of Biognosys’ relentless commitment to innovation in mass spectrometry-based proteomics and progress in life science and clinical research.”
Discovering biomarkers in cancer with next-generation plasma proteomics
The plasma proteome is an underexplored source of insights on the health state of an individual. Biognosys will present results from a deep human plasma profiling study on a cohort of 180 lung, breast, colorectal, pancreatic, and prostate cancer patients, using an early version of their next-generation Plasma Biomarker Discovery workflow, launching in November. The workflow is optimized for use on Thermo Fisher Scientific Exploris 480 and FAIMS Pro instruments. Out of the entire plasma proteome, they quantified over 2,700 proteins and identified a protein panel with a significant positive predictive value for individual cancer stages.
Andreas Huhmer, Senior Director Life Sciences Research OMICS Marketing
at Thermo Fisher Scientific:
“Biognosys has a proven track record for maximizing all innovative features of the Thermo Scientific™ Orbitrap™ mass spectrometers in state-of-the-art proteome analysis. Their new Plasma Biomarker Discovery workflow is a good example of this. The unprecedented depth and quantitative precision they can achieve, coupled with the inherently unbiased nature of mass spectrometry-based analysis, has the potential to take plasma biomarker discovery to the next level.”
Gaining insights on the immune system to support personalized drug development
Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale. Biognosys will present their immunopeptidomics workflow, optimized to provide deep and comprehensive biological insights on the immune system in large-scale clinical studies.
Turning data to insights with Spectronaut™, SpectroMine™, and SpectroDive™
Biognosys provides leading software products for proteomics data analysis. In a series of talks, their team will detail how they leverage the latest developments in Machine Learning and Deep Learning to allow deeper insights into the proteome. Biognosys is also excited to host two breakfast seminars with three guest speakers sharing their latest results from using Spectronaut in their research projects. In addition, a sneak-peak into the next planned release will be disclosed.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
“Biognosys’ software tools are among the top solutions for the analysis of proteomics data generated with Bruker instruments. Particularly the latest Spectronaut version yields spectacular performance improvements for dia-PASEF data. We invite all Bruker users to experience Spectronaut’s capabilities and enjoy the exceptional support Biognosys provides.”
Visit biognosys.com/asms2021 for a complete overview of Biognosys’ presence at ASMS.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005530/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release
Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release
New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release
Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom